Dyadic International, Inc. (DYAI)
| Market Cap | 159.21M |
| Revenue (ttm) | 2.16M |
| Net Income (ttm) | -11.60M |
| Shares Out | 28.08M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | 76.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,515 |
| Open | 5.65 |
| Previous Close | 5.62 |
| Day's Range | 5.54 - 5.75 |
| 52-Week Range | 3.15 - 8.78 |
| Beta | 0.06 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+41.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins....
Financial Performance
In 2020, DYAI's revenue was $1.60 million, a decrease of -4.71% compared to the previous year's $1.68 million. Losses were -$9.33 million, 12.2% more than in 2019.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 8.00.
News
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, a...
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein t...
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutics, and ...
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate “DYAI-100” and C1...
JUPITER, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, a...
Dyadic to Report Second Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying...
Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season
With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?
Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent
Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Cons...
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa's Rubic Consortium Aiming to Develop a...
Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries
Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Jou...
JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its propri...
The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)
The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have...
Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India
Dyadic International Inc (NASDAQ: DYAI) has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially provide...
Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)
The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of t...
Dyadic to Present at Upcoming Events
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its pr...
Could Dyadic International (DYAI) be a Dark Horse Vaccine MVP
Dyadic International Inc (NASDAQ: DYAI) continues to take strong steps as a dark horse candidate to reshape the global vaccine landscape. The company posted results and an in-depth update late last week...
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Advancing Dyadic 's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate ad...
DYAI's C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity
Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn't simply a reproduction or tie-in to the big...
A New Technology that Could Reshape the Vaccine Playing Field (NASDAQ: DYAI) (NASDAQ: AZN) (NASDAQ: MRNA) (NASDAQ: NV...
The global distribution of Covid-19 vaccines has been dramatically short of hopes and expectations, but right in line with the warnings from skeptics who know the production constraints from traditional...
Dyadic to Report First Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applyin...
Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYAI)
India is burning in Covid flames. Brazil is in basically the same shape.
Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYIA)
India is burning in Covid flames. Brazil is in basically the same shape.
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in ...
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (N...
Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations tha...
How Dyadic International Inc (NASDAQ: DYAI) Fits into the Vaccine 2.0 Gold Rush (NASDAQ: BNTX) (NYSE: JNJ) (NASDAQ: M...
Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.
Dyadic Reports 2020 Year End Results and Recent Company Progress
Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and ...
Is Dyadic International Inc (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine? (NASDAQ:...
While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately,...